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α1-antitrypsin (AAT), a circulating glycoprotein that rises during acute phase responses and 
healthy pregnancies, exhibits immunomodulatory properties in several T-cell-dependent 
immune pathologies. However, AAT does not directly interfere with T-cell responses; 
instead, it facilitates polarization of macrophages and dendritic cells towards M2-like 
and tolerogenic cells, respectively. AAT also allows NK cell responses against tumor 
cells, while attenuating DC-dependent induction of autoimmune NK cell activities. Since 
AAT-treated macrophages bear resemblance to cancer-promoting tumor-associated 
macrophages (TAMs), it became imperative to examine the possible induction of tumor 
permissive conditions by AAT. Here, AAT treatment is examined for its effect on tumor 
development, metastatic spread, and tumor immunology. Systemic AAT treatment of 
mice inoculated with B16-F10 melanoma cells resulted in significant inhibition of tumor 
growth and metastatic spread. Using NK cell-resistant RMA cells, we show that AAT 
interferes with tumor development in a CD8+ T-cell-dependent manner. Unexpectedly, 
upon analysis of tumor cellular composition, we identified functional tumor-infiltrating 
CD8+ T-cells alongside M1-like TAMs in AAT-treated mice. Based on the ability of 
AAT to undergo chemical modifications, we emulated conditions of elevated reactive 
nitrogen and oxygen species. Indeed, macrophages were stimulated by treatment with 
nitrosylated AAT, and IFNγ transcripts were significantly elevated in tumors extracted 
soon after ischemia-reperfusion challenge. These context-specific changes may explain 
the differential effects of AAT on immune responses towards tumor cells versus benign 
antigenic targets. These data suggest that systemically elevated levels of AAT may 
accommodate its physiological function in inflammatory resolution, without compromising 
tumor-targeting immune responses.
Keywords: cD8+ T lymphocytes, nitrosylation, reactive oxygen species, tumor-associated macrophages, tumor 
immunology
Abbreviations: AAT, α1-antitrypsin; BMDM, bone marrow-derived macrophage; hAAT, human α1-antitrypsin; NK cell, 
natural killer cell; NO, nitric oxide; S-NO-hAAT, S-nitrosylated human AAT; TAM, tumor-associated macrophage.
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inTrODUcTiOn
α1-Antitrypsin (AAT) is currently gaining recognition as an 
immunomodulatory agent capable of improving outcomes in a 
variety of immune conditions (1, 2). AAT levels rise physiologi-
cally in the circulation during acute phase responses, as well as 
during the third trimester of pregnancy. AAT is routinely infused 
to individuals who lack sufficient circulating AAT due to a genetic 
deficiency (AATD) (3). According to preclinical studies, treat-
ment with AAT induces long-term tolerance to allogeneic islet 
transplants (4, 5) and alleviates aspects of autoimmune diabetes 
(6), graft-versus-host disease (GvHD) (7), inflammatory bowel 
disease (8), and multiple sclerosis (9). Some of these target diseases 
are presently assessed in multiple Phase II clinical trials. While 
AAT has been thoroughly documented as an inhibitor of inflam-
matory serine proteases, primarily neutrophil elastase, cathepsin 
G, and proteinase 3 (1, 2), evidence suggests a mechanism of 
operation independent of protease inhibition that extends toward 
immune-oriented innate cellular targets (1, 2). As such, evidence 
points to effects dependent upon several environment-dependent 
covalent modifications of AAT, such as that take place in envi-
ronments rich in reactive oxygen species and/or reactive nitrous 
species; indeed, protease targets of naïve AAT (1, 5), oxidized 
AAT (5, 10, 11), and nitrosylated AAT (S-NO-AAT) (12) appear 
to be largely separate.
Dendritic cells (DCs) and macrophages are among the most 
incessant cellular targets of AAT (13, 14); treating these cells 
with AAT, concomitant with inflammatory stimulation, results 
in reduced inflammatory activation profiles and an apparent 
redirection of the mode of activation toward an immunomodu-
latory phenotype (13, 14). Specifically, AAT-treated animals that 
underwent allogeneic skin and islet transplantation exhibited 
DCs with a semi-mature DC (smDC) phenotype (14); these DCs 
secreted anti-inflammatory cytokines, such as IL-1 receptor 
antagonist (IL-1Ra) (15), IL-10 (14), and transforming growth 
factor β (TGFβ) (4), and promoted the differentiation of regula-
tory T cells (Tregs) (14). Tumor-associated DCs (TADCs) are 
DCs present in the periphery of solid tumors, which have been 
suggested to act as immune suppressors (16). While these cells 
seem to bear certain similarities to AAT-treated DCs, the influ-
ence of AAT over TADCs has yet to be examined. AAT-treated 
macrophages exhibit a similar trend by polarizing toward the 
M2-like profile in the presence of AAT and various inflamma-
tory stimuli (13). Importantly, while AAT treatment does not 
directly affect isolated T (4, 5) or natural killer (NK) (17) cell 
responses, AAT indirectly promotes Treg differentiation (14) 
and alters NK cell responses in mixed cultures, thus diminish-
ing cytotoxic CD8+ effector T cell expansion (14). AAT further 
acts indirectly through DC-mediated mechanisms to divert 
NK cells away from non-authentic threats (17). It was recently 
established that while isolated NK cell responses against tumor 
cells remain intact in the presence of AAT, NK cell activities are 
indirectly modulated by reduced cross-activation signals from 
stimulated DCs (17).
While literature regarding the precise influence of AAT over 
tumor development is strikingly scarce, several studies have 
established that AAT treatment inhibits both tumor development 
and tumor angiogenesis in mice (18), and that AAT treatment 
of MCF-7 breast cancer cells had resulted in reduced tumor 
cell proliferation rates and invasiveness (19–21). Nonetheless, 
these data do not address the possible influence of AAT over 
 leukocyte–tumor interactions that are of critical importance in 
tumor immunology.
Versatility and plasticity are among the hallmarks of mac-
rophages (22–24). When exposed to various cytokines and 
environmental factors, macrophages may polarize and acquire 
either pro- or anti-inflammatory characteristics. Pro- and 
anti-inflammatory macrophages are often termed M1-like and 
M2-like macrophages, respectively (22–24). M1-like and M2-like 
macrophages represent the extremes of a wide continuum of 
possible polarization states, with numerous intermediary states, 
and suitable stimulation may redirect polarized macrophages 
across the spectrum. Indeed, macrophage repolarization has been 
demonstrated to be involved in ameliorating disease progression 
in models of type 1 diabetes (25), inflammatory bowel disease 
(26–28), and multiple sclerosis (29).
M2-like macrophages share numerous characteristics with 
tumor-associated macrophages (TAMs) that hold a critical role in 
tumor progression (30–33). TAMs are derived from blood-borne 
inflammatory monocytes that infiltrate into the tumor tissue and 
polarize toward the M2-like phenotype (34, 35). AMs engage in 
an intricate bidirectional cross-talk with local tumor cells (31, 
36–38), leukocytes (39–42), fibroblasts (43), and endothelial 
cells (44). TAMs facilitate tumor progression by promotion of 
angiogenesis (44–46), secretion of growth factors such as TGFβ 
and vascular endothelial growth factor (VEGF) (30–33), and 
suppression of antitumor lymphocytes (31, 47–49). In particular, 
CD8+ T cells are locally inhibited by TAM-derived IL-10 and 
TGFβ and are compromised by TAM-induced Tregs (31, 50, 51). 
In contrast, M1-like macrophages elicit cytotoxic responses from 
CD8+ T cells, through the secretion of IL-12, IL-18, type I IFNs, 
and tumor necrosis factor α (TNFα) (31, 52, 53), and can directly 
kill tumor cells through the release of nitric oxide (NO) (53). 
Importantly, treatment of pro-tumor TAMs with IFNγ (54) or 
with augmentation of the NF-κB pathway (55) has been shown 
to reverse TAM polarization and induce a pro-inflammatory 
phenotype.
In the present study we employ several in vivo tumor inocula-
tion models and assess their outcomes under AAT therapy. We 
specifically examine intra-tumor leukocyte composition and 
activation profiles and the contribution of AAT-modified innate 
cells toward effective CD8+ antitumor T cell responses. While 
assessment of unmodified human α1-antitrypsin (hAAT) has 
uniformly suggested anti-inflammatory characteristics, factors 
prevalent in tumor environments such as hypoxic conditions 
(11) or elevated concentrations of NO (12) have been suggested 
to alter the effects of AAT. Therefore, covalent environment-
based modifications of AAT are addressed using settings that 
incorporate nitrosylated AAT, as well as an ischemia–reperfusion 
(IRP) model that examines the function of AAT in a hypoxic 
environment characteristic of tumors. These models serve to 
investigate the hypothesis that AAT may attain an appropriate 
context-specific and immunocyte-specific activity profile so as to 
enhance immune antitumor responses.
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MaTerials anD MeThODs
Mice
Wild-type (WT) C57BL/6 mice were purchased from Harlan 
Laboratories (Rehovot, Israel). Transgenic hAAT+/+ mice with 
C57BL/6 background were engineered as described (56) and bred 
in-house. All animal studies were approved by the Animal Care 
and Use Committee, Ben-Gurion University of the Negev. Female 
6- to 10-week-old mice were used in all experiments.
cell line cultures
The B16-F10 cell line (murine melanoma cell line, no. CRL-
6475) was purchased from American Type Cell Cultures 
(ATCC, Manassas, VA, USA), while the RMA and RMA-S cell 
lines (murine lymphoma origin) were generously provided by 
A. Porgador (Ben-Gurion University of the Negev). RMA-S cells 
were originally generated by permanent silencing of MHC class 
I expression in RMA cells; they are therefore non-sensitive to 
MHC class I-restricted CD8+ T cells, but sensitive to NK cells 
due lack to of MHC class I-dependent inhibition of NK cells 
(57, 58). Cells used in all experiments were from the first six 
passages. B16-F10 cells were cultured in DMEM medium, and 
all other cell lines were cultured in RPMI-1640 medium, sup-
plemented with 10% heat-inactivated FBS, 2 mM l-Glutamine, 
50  U/ml penicillin, and 50  μg/ml streptomycin (all from 
Biological Industries, Beit HaEmek, Israel) under standard con-
ditions. Where stated, cell cultures were treated with indicated 
concentrations of human serum-purified hAAT (Glassia™, 
Kamada Ltd., Nes-Ziona, Israel). Cells were routinely verified 
to be mycoplasma-free.
generation and activation of and BMDMs
Bone marrow-derived macrophages (BMDMs) were generated 
by flushing of murine tibia and femur bones with sterile PBS 
and culturing of bone marrow cells in complete RPMI-1640 
medium supplemented with 50 μM β-mercaptoethanol (Sigma-
Aldrich, Rehovot, Israel). Cells were cultured with granulocyte–
macrophage colony-stimulating factor (GM-CSF) (20  ng/ml, 
Peprotech, Rocky Hills, NJ, USA) for 6  days of culturing, as 
described (59). Cells were routinely verified to be >90% F4/80+. 
For activation experiments, cultured BMDMs were seeded at 
2 × 105 cells per well in 200 μl of standard RPMI-1640 medium 
and pretreated with hAAT at 0.5 or 2.5  mg/ml, as indicated, 
S-NO-AAT at 2.5 mg/ml or GSNO (Chem-Impex International, 
Wood Dale, IL, USA) at 27.5 μM. After 24 h, cells were care-
fully washed with PBS and activated with recombinant IFNγ 
(10  ng/ml, R&D Systems, Minneapolis, MN, USA) and IL-1β 
(10 ng/ml, Prospec, East Brunswick, NJ, USA), with or without 
coculturing with RMA cells at a ratio of 1:2 (RMA:BMDM) 
for 24  h. IL-6 release to the supernatant was quantified with 
specific ELISA (Biolegend, San Diego, CA, USA). Lactate 
dehydrogenase (LDH) release to the supernatant was quantified 
with a Non-Radiological Cytotoxicity Kit (Promega, Madison, 
WI, USA). Nitric oxide release to the supernatant was evalu-
ated by Griess kit (Promega) according to the manufacturer’s 
instructions.
Tumor inoculation Models
In the B16-F10 primary tumor model, hAAT+/+ and C57BL/6 
were untreated prior to inoculation of B16-F10 cells (5 × 105 cells 
per animal, i.f.p.) or after inoculation. For in vivo transfection of 
hAAT, mice underwent hydrodynamic injections (HDI) of pEF-
hAAT plasmid (100 μg per animal, i.v.), as described elsewhere 
(60). Control animals received the same volume of PBS, and 
serum samples were obtained routinely. Circulating hAAT levels 
were quantified with specific ELISA (Immunology Consultants 
Laboratory, Portland, OR, USA). Tumor length and width were 
measured with standard calipers. For examination of IRP effects 
in the B16-F10 primary tumor model, tumor-bearing limbs were 
subjected to unilateral ischemia by the application of a tourniquet 
for 3 h. Animals were sacrificed 2 h after removal of tourniquets, 
and total foot tissue from the immediate inoculation site was 
excised and dissociated by mechanical disruption with the 
gentleMACS Dissociator and C tubes (Miltenyi Biotec, Cologne, 
Germany). Purified RNA was then utilized for gene transcription 
quantification.
In the B16-F10 lung metastasis model, mice were treated 
with hAAT (2 mg per animal) or PBS 1 day prior to tumor cell 
inoculation and every third day thereafter. Mice subsequently 
underwent B16-F10 inoculation (1 ×  106  cells per animal, i.v.) 
and were sacrificed after 17 days. Peripheral blood was perfused, 
and lungs were fixed by perfusion of 4% paraformaldehyde prior 
to production of paraffin blocks. Metastatic foci in the lungs were 
subsequently counted by microsurgery and by identification of 
foci in H&E slides.
In the RMA/RMA-S and RMA/B16-F10 tumor cell clearance 
models, mice were treated with hAAT (2  mg per animal) or 
PBS 1 day prior to tumor cell inoculation. Inoculated cells were 
stained differentially with lipophilic tracers (RMA stained with 
DiL, RMA-S, and B16-F10 with DiD) (Thermo-Fisher, Waltham, 
MA, USA), mixed at a 1:1 ratio, and inoculated (1 × 107 total cells 
per animal, i.v.). Animals were sacrificed after 5  h, lungs were 
removed and dissociated, and lung cells were analyzed with flow 
cytometry.
In the RMA/RMA-S tumor model, mice were treated with 
hAAT (2 mg per animal) or PBS 1 day prior to tumor cell inocu-
lation and every third day thereafter. Inoculation of RMA and 
RMA-S (1 × 105 cells per animal, s.c.) was conducted either simul-
taneously to opposing flanks or separately to the right flank 24 h 
later, and tumor length and width were measured with standard 
calipers. Depletion of CD8+ T cells was conducted as described 
previously (61), and depletion outcomes were routinely verified to 
be the absence of >95% of CD8+ T cells compared to non-ablated 
mice. In certain experiments, RMA tumors were dissociated, and 
total tumor RNA was purified by mechanical disruption with 
the gentleMACS Dissociator and C tubes (Miltenyi Biotec) and 
utilized for gene transcription quantification.
Primary T cell separation and activation 
assays
CD8+ T cells were purified from spleens and RMA tumors of 
tumor-bearing mice 13  days after inoculation of tumors by 
magnetic purification kit (Stemcell Technologies, Vancouver, 
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BC, Canada) as per the manufacturer’s instructions. Cells were 
then incubated in 10% RPMI-1640 growth medium (Biological 
Industries) and cocultured with RMA cells (1:1 ratio) for 24 h. 
Cells were then stained for relevant intracellular markers, and 
TNFα release to the medium was quantified with specific ELISA 
(Biolegend, San Diego, CA, USA).
immunofluorescence
Immunofluorescent (IF) staining was performed with tissues 
fixed with 10% formaldehyde, dehydrated with ethanol, cleared in 
xylene, and embedded in paraffin. Tissues were sectioned with a 
microtome and 4 μm sections and stained with H&E or subjected 
to IF staining. For IF staining, PE-conjugated α-CD45 antibody 
was used at 1/20 dilution overnight (EM-05, Exbio, Prague, Czech 
Republic). Nuclei were stained with DAPI at 1/1,000 dilution 
(Sigma-Aldrich). Cells were examined using a 405-nm excitation 
laser line for DAPI and a 496-nm laser line for PE. Microscopy 
was performed using an Olympus Fluoview FV1000 confocal 
microscope.
Flow cytometry
In all experiments, 1  ×  106  cells were suspended in flow 
cytometry buffer consisting of PBS (Biological Industries) with 
1% bovine serum albumin (BSA, Biological industries), 0.1% 
sodium azide, and 2 mM EDTA (Sigma-Aldrich). Fc blocking 
was conducted with α-CD16/32 antibody (Biolegend) for 20 min 
at 4°C. Staining was performed for 20 min at 4°C with the fol-
lowing antibodies: α-CD11c-APC (N418), α-MHC class II-PE 
(M5/114.15), α-F4/80-APC (BM80), α-TLR4-PE (MTS510), 
α-CD40-PE-Cy7 (3/23), α-CD86-PE (GL-1), α-CD8-PE-Cy7 
(53-6.7), and α-CD11b-Pacific Blue (M1/70), all from Biolegend. 
Intracellular staining was conducted by treatment of target cells 
with Monensin solution (Biolegend) diluted 1/1,000 in standard 
RPMI-1640 growth medium for 5 h, followed by washing, stand-
ard Fc receptor blocking, surface antigen staining and fixation 
with Fixation Buffer (Biolegend) for 20  min. Cells were sub-
sequently washed with Intracellular Staining Permeabilization 
Wash Buffer (Biolegend), and intracellular antigens were 
stained with the following antibodies: α-TNFα-Pacific Blue 
(MP6-XT22), α-IL-10-APC (JES5-16E3), α-IFNγ-AlexaFluor 
647 (XMG1.2), and α-perforin-PE (BioOMAK-d) (all from 
Biolegend). For 7-AAD cellular viability assay, cultured cells 
were washed and introduced 7-AAD (Biolegend) diluted 1/200 
in flow cytometry buffer. Cells were read in a flow cytometer 
within 10 min of exposure to 7-AAD reagent. Samples were read 
using BD Canto II (BD Biosciences, Singapore), and data were 
analyzed by FLOWJO 7.6.3 software (Flowjo, LLC Data Analysis 
Software, Ashland, OR, USA).
real-time Pcr assay
Total RNA extracted from surgically removed tumor tissues 
was purified with total RNA purification kit (Norgen Biotek 
Corp., Thorold, ON, Canada). After quantification of RNA 
by NanoDrop spectrophotometer (ND-1000, NanoDrop 
Technologies, Wilmington, DE, USA), reverse transcription of 
RNA to cDNA was performed using qScript™ cDNA synthesis 
kit (Quanta BioSciences, Gaithersburg, MD, USA) and 1 μg of 
template RNA and a blend of random hexamers and oligo (dT) 
primers. Quantification of gene transcription was performed 
with the StepOnePlus Real-Time PCR system and the Fast SYBR 
Green Master Mix (Applied Biosystems, Foster City, CA, USA). 
The following primers were used for PCR amplification: CD14: 
Fw 5′-CATTTGCATCCTCCTGGTTTCTGA Rev 5′-GAGT 
GAGTTTTCCCCTTCCGTGTG, IFNγ: Fw 5′-GTCATTGAA 
AGCCTAGAAAGTC Rev 5′-GTTGTTGACCTCAAACTTGG, 
GAPDH: Fw 5′-TCAACAGCAACTCCCACTCTTCCA Rev 
5′-ACCCTGTTGCTGTAGCCGTATTCA, VEGF: Fw 5′-CAG 
GCTGCTGTAACGATGAA Rev 5′-AATGCTTTCTCCGCTC 
TGAA, α-SMA: Fw 5′-AGCACAATACCAGTTGTACG Rev 
5′-ATAGAACACGGCATCATCAC, IL-1Ra: Fw 5′-CACCGGA 
AGAGCCCCTTATAG Rev 5′-TGCAAAAGTTGTTCCTCAG 
GC, IL-12p40: Fw 5′-TGGCGAACCTGGATGGTTT Rev 5′-GG 
GAGAGTCGGTTGCTTACC, and IL-10: Fw 5′-GCTCTTACT 
GACTGGCATGAG Rev 5′-CGCAGCTCTAGGAGCATGTG.
Production of s-nO-aaT
Human α1-antitrypsin (20 mg/ml or 450 μM) was reduced by 
incubation with 50 mM DTT for 10 min at 37°C. Excess reduc-
ing agent was removed by gel filtration using Sephadex G-25 
columns (GE Healthcare) equilibrated in the nitrosylation buffer 
(25 mM HEPES pH 7.4, 0.1 mM EDTA, 0.2 mM diethylenetri-
aminepentaacetate, 10  μM neocuproine, and 100  mM NaCl). 
Reduced hAAT was then incubated for 30 min with 1,000 μM 
diethylamine NON-Oate (Cayman Chemical, MI, USA) fol-
lowed by adding additional 500 μM diethylamine NON-Oate for 
more 30 min at 37°C. After excess NO donor was removed by 
Sephadex G-25 chromatography, the S-nitrosylation efficiency 
was calculated by measuring protein concentration and number 
of nitrosylated thiols. Protein concentration was determined 
using Bicinchoninic acide (BCA) protein assay kit (Santa Cruz) 
with hAAT in known concentrations as a calibration curve. 
hAAT’s nitrosylated thiols quantification was carried out by 
Saville–Griess assay (62). Briefly, S-nitrosylated human AAT 
(S-NO-hAAT) was incubated in assay buffer (1% sulfanilamide, 
0.1% N-(1-naphthyl)ethylenediamine dehydrochloride, 1% 
HCl) in the absence or presence of 1  mM HgCl2 for 30  min, 
and absorbance readings were measured at 540  nM by ELISA 
plate reader. S-nitrosoglutathione (GSNO) treated identically 
served as a standard curve, and mercury-dependent absorbance 
was converted to SNO concentrations. hAAT’s nitrosylation 
efficiencies were more than 50%. After production, S-NO-
hAAT was aliquted into dark tubes and stored at −80°C for a 
single thaw. Saville–Griess assay was also used for S-NO-hAAT 
transnitrosylation; after treating peritoneal macrophages with 
100 mM N-ethylmaleimide (NEM) or PBS for 15 min at RT, they 
were introduced to S-NO-hAAT. Medium supernatant samples 
were taken in indicated time points, and the S-nitrosylated 
protein was measured by Saville–Griess assay.
statistical analysis
Statistical analysis results are expressed as mean ± SEM. Unpaired 
two-tailed Student’s t-test was used to assess the differences 
between treated groups and control. A p-value of ≤0.05 was 
considered significant.
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resUlTs
comparison between constitutively 
elevated haaT and Plasmid-Derived 
circulating haaT in a B16-F10 Footpad 
Tumor Model
In order to exclude the possibility that tumors might thrive in 
conditions of elevated levels of circulating hAAT, the initial 
assessment of the outcomes of hAAT treatment on development 
of B16-F10 primary tumors was performed. Tumor development 
after i.f.p. inoculation of B16-F10 cells was tested in WT mice 
and in mice that constitutively overexpress hAAT (hAAT+/+) (56). 
Importantly, hAAT+/+ mice were used in multiple experimental 
settings by our group as well as others and constitutively display 
similar steady-state immunological background (9, 63, 64). 
As shown in Figure 1A (i), while WT mice displayed measur-
able tumors within the overall expected time frame (~30 days), 
hAAT+/+ mice developed discernable tumors at a delayed time 
point (~42 days), and these tumors failed to thrive.
The significantly reduced development of tumors observed in 
hAAT+/+ mice required that we investigate the in vivo antitumor 
properties of hAAT in this model. Transcription levels of pro-
tumor and antitumor cytokines that are primarily leukocyte-
derived in the tumor environment were therefore evaluated. As 
shown in Figure  1A (ii), hAAT+/+ mice displayed significantly 
reduced VEGF transcript levels and elevated IL-12p40 and IFNγ 
transcript levels, as compared to WT animals.
Tumor development was further evaluated using an in  vivo 
transfection model. A hAAT-expressing plasmid (pEF-hAAT) 
was introduced into WT mice utilizing the HDI model [Figure 1A 
(iii)]. Control WT mice underwent HDI with identical volumes 
of PBS. Mice were then inoculated i.f.p. with B16-F10 cells, and 
tumor size was continuously examined. As shown, mice express-
ing plasmid-derived hAAT displayed micrograms of circulating 
hAAT, albeit for a limited period of time (left). Primary tumor 
development in these mice was significantly delayed and dimin-
ished compared to parallel time points in control mice (right). In 
contrast to in vivo models examined, in vitro tumor cell prolifera-
tion was not inhibited by hAAT (Figure 1B left), and tumor cells 
displayed intact inducible MHC class I expression when treated 
with hAAT (Figure 1B right).
The interface between Tissue-infiltrating 
B16-F10 cells and local leukocyte 
responses: Metastatic spread
In order to examine the outcomes of hAAT treatment on periph-
eral tumor cell infiltration, i.v. inoculation of B16-F10 cells was 
conducted. Lung metastatic nodules were counted after 17 days 
(Figure  2A). As shown, metastatic spread was significantly 
reduced in mice treated with hAAT. During histological exami-
nation of explanted lungs (Figure 2B), metastatic nodules were 
identified and PBS-treated animals tumor foci that were spatially 
separate from leukocytic infiltrates. In contrast, hAAT-treated 
mice displayed a lower degree of leukocyte infiltration, but 
immunocytes were interspersed between tumor cells, as dem-
onstrated by the higher number of metastatic node-infiltrating 
CD45+ leukocytes in hAAT-treated mice. At large, it appears 
that hAAT treatment resulted in reduction of metastatic burden, 
without a significant reduction in leukocyte recruitment to the 
vicinity of tumor foci.
nK cell- and T cell-sensitive Tumor 
Models
The influence of hAAT therapy over in  vivo tumor cell clear-
ance without prior exposure to tumor cells was examined. 
Animals were treated with hAAT and 24  h later inoculated 
i.v. with a 1:1 ratio of NK cell-sensitive RMA-S lymphoma 
cells (65) and NK cell-insensitive RMA T cell lymphoma cells 
(66), both differentially stained with lipophilic dyes. After 5 h, 
animals were sacrificed, and the presence of both cell types in 
the lungs was examined by flow cytometry. As shown in Figure 
S1A in Supplementary Material, the ratio of the two cell types 
at the end of 5 h was uniform between PBS- and hAAT-treated 
mice (approximately eight times as many NK-insensitive RMA 
cells than NK-sensitive RMA-S cells). When a similar experi-
mental set-up was performed with RMA and B16-F10 cells, 
PBS- and hAAT-treated mice again displayed similar ratios 
of NK-insensitive RMA cells and NK-sensitive B16-F10 cells 
(Figure S1B in Supplementary Material).
The two main lymphocytic compartments responsible for 
effective in vivo clearance of tumor cells are NK cells (67) and 
CD8+ T cells (68). In order to specifically determine the effects of 
hAAT on NK cell and cytotoxic CD8+ T cell activity in the context 
of in vivo tumor development, mice were simultaneously inocu-
lated s.c. with CD8+ T cell-sensitive, NK cell-insensitive RMA 
cells to the right flank (69, 70), and with CD8+ T cell-insensitive, 
NK cell-sensitive RMA-S cells to the left flank (Figure 3A), and 
tumor size was determined throughout a 24-day follow-up. As 
shown, hAAT-treated mice displayed significant inhibition of 
RMA tumor development. NK cell-sensitive RMA-S tumors were 
slow to grow and unaffected by hAAT therapy. Importantly, when 
mice were subjected to identical hAAT treatment regimens and 
inoculated separately with RMA or RMA-S cells, development 
patterns of both types of tumors were similar to those observed 
in mice inoculated with both cell lines simultaneously (Figure S2 
in Supplementary Material).
The involvement of CD8+ T cells in tumor growth inhibition 
by hAAT was then challenged. RMA tumor development was 
examined in mice depleted of CD8+ T cells with or without hAAT 
treatment, as followed over 17 days. As shown in Figure 3B left 
(follow-up) and right (day 17), hAAT-mediated inhibition of 
RMA tumor growth was compromised by CD8+ T cell depletion. 
These outcomes suggest that the observed inhibition is dependent 
on CD8+ T cell activity, and that NK cells retain intact antitumor 
capacity during in vivo hAAT treatment. As hAAT lacks direct 
influence on T cell responses (4, 71), an indirect avenue of 
modulation by way of innate immune cell-alteration was next 
considered.
Tumor-associated innate leukocyte 
Populations in haaT-Treated Mice
The influence of hAAT on innate leukocyte interaction with 
tumors was examined in tumor-bearing mice. Solid RMA 
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tumors were dissociated in animals treated with hAAT, depleted 
of CD8+ T cells, or a combination of both, and tumor-infiltrating 
leukocyte populations were depicted. As shown in Figure  4A 
solid bars, a significantly elevated percentage of tumor-infiltrating 
F4/80+CD11b+CD40+ cells was detected, agreeing with greater 
prevalence of M1-like TAMs in hAAT-treated mice (72–74). 
Importantly, TAMs present in hAAT-treated mice that were 
depleted of CD8+ T cells displayed a profile similar to PBS-treated 
mice (Figure  4A empty bars). CD11c+ DCs detected in RMA 
tumors of hAAT-treated mice contained significantly greater per-
centages of CD40+ DCs (Figure S3 in Supplementary Material), 
similar to F4/80+CD11b+ TAMs. Percentages of CD11c+CD40+ 
DCs in hAAT-treated mice that were depleted of CD8+ were 
similar to percentages detected in PBS-treated mice (Figure S2 
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in Supplementary Material), again conforming to observations 
made for F4/80+CD11b+ TAMs.
The profile of cytotoxic CD8+ T cells in hAAT-treated mice 
was tested in vivo. Primary RMA tumors were dissociated, and 
tumor-infiltrating T cell populations were stained for intracel-
lular perforin and IFNγ. As shown in Figure 4B top, while total 
tumor-associated CD8+ T cell percentages were similar between 
PBS- and hAAT-treated mice, tumor-infiltrating CD8+ T cells in 
hAAT-treated mice were found to express significantly greater 
levels of perforin and IFNγ. Splenocytes from tumor-bearing 
mice (Figure 4B bottom) appear to have been unaffected by the 
treatment, with a possible marginal trend of the spleen toward 
being depleted from perforin/IFNγ-expressing T cells. These 
results suggest that CD8+ T cells in hAAT-treated mice may be 
more prone to antitumor cytotoxic functions, in the examined 
models.
In Vitro activation of cD8+ T cells from 
Tumor-Bearing Mice
Magnetically purified tumor and spleen CD8+ T cells were 
cocultured with RMA target cells for 24 h. Cells were stained for 
intracellular perforin, TNFα, and (not shown) IFNγ. As depicted 
in Figure 4C, perforin and TNFα staining levels were significantly 
greater in all examined CD8+ T cell populations when RMA 
target cells were present, and while perforin and TNFα levels 
were similar for spleen CD8+ T cells from PBS and hAAT-treated 
mice (solid bars), tumor CD8+ T cells from hAAT-treated mice 
expressed significantly greater perforin and TNFα levels than 
either spleen or tumor CD8+ T cells from PBS-treated cells 
(empty bars). Intracellular IFNγ staining was not significantly 
elevated by the presence of RMA target cells and was similar in all 
examined CD8+ T cell populations (not shown). Release of TNFα 
to the supernatant was also examined (Figure 4D), induced by 
coculture of RMA cells with all examined CD8+ T cell popula-
tions. As shown, TNFα levels were consistent between spleen 
CD8+ T cell–RMA cocultures, while CD8+ T cell originating from 
tumors of hAAT-treated mice released significantly higher levels 
of TNFα (second solid bar from the right), thus conforming to the 
intracellular staining shown for TNFα (Figure 4C).
Unique Tumor inflammatory gene 
expression under haaT Treatment
In order to examine inflammation-associated gene expression in 
the tumor, total RMA tumor tissue RNA was purified, and a series 
of real-time QPCR gene transcription assays was performed. 
Animal groups were comprised of hAAT-treated CD8+ T cell-
depleted groups. As shown in Figure 5, a significant reduction 
in VEGF and α-SMA transcript levels was detected in hAAT-
treated mice regardless of CD8+ T cell depletion. Unexpectedly, 
transcription of IL-1Ra was also reduced in hAAT-treated mice, 
although to lesser extent. IL-12p40 and CD14 transcripts were 
conversely found to rise in hAAT-treated mice, and likewise unaf-
fected by CD8+ T cell depletion. Foxp3 and IL-10 transcription 
levels were similar in all groups; IFNγ transcription was found to 
be higher in hAAT-treated mice, but levels were similar to PBS-
treated mice when hAAT administration was combined with 
CD8+ T cell depletion.
These results demonstrate that hAAT treatment alters inflam-
mation-associated gene expression in tumors; angiogenesis and 
M2-like macrophage-associated gene transcription appears to be 
decreased, while M1-like macrophage gene transcription exhibits 
a tendency to rise regardless of the presence of cytotoxic CD8+ 
T cells (30).
Importantly, IFNγ transcription was significantly increased by 
hAAT treatment only when CD8+ T cells were intact.
effect of haaT on Macrophage–rMa 
cocultures
Thus far, evidence has been gained regarding the effects of hAAT 
on in  vivo tumor immunology with the particular observation 
of M1-like macrophage polarization and associated induction of 
CD8+ T cell antitumor cytotoxicity, an intriguing opposite trend 
to the overall knowledgebase regarding hAAT and inflamma-
tion (4, 5, 9, 14, 17, 60). In order to clarify the mechanism by 
which hAAT may act to affect tumor-infiltrating macrophages 
in such a context-dependent manner, BMDMs were pretreated 
with hAAT and then cocultured with RMA tumor cells, with or 
without stimulation with recombinant IFNγ and IL-1β. After 
72 h, BMDMs were stained and analyzed for M1-like macrophage 
markers, TLR4 and CD40 (Figure 6A). As shown, the response 
of stimulated BMDMs to RMA cells was effectively inhibited 
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(c,D) Purified splenic or tumor-infiltrating CD8+ T cells (1 × 105 cells per well in triplicate) were incubated for 24 h with or without cultured RMA cells (CT:RMA, 
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by pretreatment with hAAT. Consistent with this finding, IL-6 
and NO release to the supernatant were diminished by hAAT 
(Figure 6B).
nitrosylated haaT Facilitates M1-like 
BMDM stimulation
Considering that hAAT is broadly regarded as an anti-inflamma-
tory agent (1), the possibility that local covalent modifications 
might alter its function in a context-dependent manner was 
examined. Treatment of BMDMs with cysteine-nitrosylated 
hAAT (S-NO-hAAT) revealed a unique pattern (Figure  7A). 
BMDMs were stimulated with IFNγ and IL-1β and treated by 
either hAAT, S-NO-hAAT, or GSNO (at equal molar ratios of NO 
to S-NO-AAT) before being exposed to RMA cells. The response 
of BMDMs was depicted by cell-specific staining for surface CD86 
and intracellular IL-10. As shown in Figure 7A (i), while naïve 
hAAT (red) reduced BMDM expression of CD86 and elevated the 
expression of IL-10, treatment with S-NO-hAAT largely reversed 
this phenotype; the presence of GSNO had no discernable effect. 
Treatment of cell cultures with S-NO-hAAT also significantly 
raised NO release, as depicted in Figure 7A (ii); importantly, NO 
levels in S-NO-hAAT-treated cultures were significantly greater 
than NO levels in GSNO-treated wells (gray), suggesting that the 
rise in NO release stems from increased activation of BMDMs 
rather than the molecular introduction of free NO.
The influence that S-NO-hAAT may have on tumor cell sur-
vival was next addressed. Tumor cells (RMA) were treated in vitro 
with S-NO-hAAT (Figure  7B). Control treatments consisted 
of unmodified hAAT, nitrosylated glutathione (GSNO) at an 
equimolar concentration, and doxorubicin (Dox.) as a positive 
control for tumor cell death. Cells were seeded and counted after 
24 h. As shown in Figure 7B (i), wells cultured with S-NO-hAAT 
were found to contain significantly lower cell numbers at 24 h 
compared to control or wells cultured with either hAAT or GSNO. 
After 48 h, supernatants were collected for assessing LDH release, 
and cell death events were recorded by staining with 7-AAD. As 
shown in Figure 7B (ii) and (iii), supernatant LDH levels were 
significantly higher in wells added S-NO-hAAT, while staining 
with 7-AAD yielded significantly greater staining percentages in 
cells treated with S-NO-hAAT. These results suggest that tumor 
cell viability may be inhibited to a certain extent by the presence 
of S-NO-hAAT; this effect is not observed when naïve hAAT or 
GSNO are added. Interestingly, naïve hAAT appeared to have 
diminished the readout of cell death in RMA cells but did not 
alter the total amount of tumor cells. Thus, if in situ local tumor 
conditions are rich in NO, they may modify hAAT to a form, 
which facilitates tumor cell susceptibility.
ischemia–reperfusion of Tumor Tissue 
Differentially alters cytokine Transcription 
in WT and haaT+/+ Transgenic Mice
Temporary oxygen deprivation followed by arterial blood irri-
gation induces numerous changes in gene transcription levels 
(75). Using B16-F10 tumor-bearing WT and hAAT+/+ mice, 
we performed IRP of tumor-bearing extremities (Figure  7C) 
and determined changes in VEGF, IL-12p40, IFNγ, and IL-10 
transcription levels in the immediate inoculation site. As 
shown, tumors collected from WT animals that underwent IRP 
displayed a rise in VEGF and IFNγ transcription levels and a 
decline in IL-12p40 and IL-10 levels. While the same overall 
trend is readily observed in tumors from hAAT+/+ animals, 
there appears to be an even greater presence of VEGF and IFNγ 
(4.1- and 1.78-fold from IRP-treated tumors collected from WT 
mice, respectively).
DiscUssiOn
The immunomodulatory effects of AAT in autoimmune and 
allogeneic immune responses have been thoroughly studied, 
consistently demonstrating amelioration of pathological pro-
cesses and induction of long-lasting tolerance. AAT is known 
to promote leukocyte profiles associated with inflammatory 
resolution and tissue regeneration (1, 76). While tumors may 
theoretically benefit from an immunomodulatory environment 
rich in growth factors and with reduced lymphocytic activation, 
one must consider that numerous physical and immunological 
differences exist between autoantigen-driven immune models 
and tumor-related settings. Indeed, routine AAT treatment, 
as afforded to individuals with AAT deficiency (AATD) (77), 
has been commonplace for over three decades, and clinical 
evidence points to a reduction in bacterial infections in AAT-
treated AATD individuals (76) as well as a lack of rise in tumor 
development rates. In fact, if untreated, individuals with AATD 
display elevated rates of lung cancer (78, 79), gastrointestinal 
cancer (80, 81), and liver cancer (82, 83).
The scarcity of knowledge regarding the involvement of AAT 
in tumor development and tumor immunology necessitates a 
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careful examination of tumor development dynamics in immune-
competent settings. Such an examination must elucidate the effects 
of various AAT administration regimens. Initial experiments 
performed in this study made use of a model in which B16-F10 
melanoma cells were inoculated into hAAT+/+ transgenic mice 
that constitutively overexpress hAAT (56). We were surprised to 
find that B16-F10 tumors failed to thrive over extended periods 
of time. Since transgenic animal colonies are at risk of harboring 
discrepancies from their founders and crossbred background 
strains, the study was subsequently conducted in WT mice that 
were either exogenously injected with serum-purified clinical-
grade hAAT or transfected in  vivo with a hAAT-expressing 
liver-directed plasmid. The outcomes were indeed in line with 
tumor growth suppression in hAAT+/+ mice, and subsequent 
experiments were set forth to explore the cellular responders to 
hAAT therapy under these conditions.
In vitro treatment of B16-F10 cells with hAAT demonstrated 
that cellular viability is not directly reduced by hAAT, and that 
IFNγ-induced upregulation of MHC class I expression remains 
intact in its presence. A significant reduction in VEGF transcrip-
tion and elevation in IL-12p40 and IFNγ transcription levels was 
detected in tumors from hAAT+/+ mice. These findings suggest 
the presence of an antitumor cytotoxic response rather than 
direct oncological stress. Moreover, in the in vivo hAAT-plasmid 
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at 2.5 mg/ml), GSNO (27.5 μM), or doxorubicin (60 μM). (i) Cells were stained with trypan blue, and the population of viable cells was determined after 24 h. (ii) LDH 
release after 48 h. (iii) 7-AAD staining. Mean ± SEM, *p < 0.05, ***p < 0.001. Unpaired two-tailed Student’s t-test was employed to assess differences between 
groups. (c) Effect of ischemia–reperfusion on intra-tumor gene expression profile during hAAT treatment. C57BL/6 mice (n = 3 per group) were pretreated with 
hAAT (2 mg per animal, i.p.) 24 h prior to inoculation of B16-F10 melanoma cells (5 × 104 cells per mouse, i.f.p.). Mice were subjected to limb ischemia–reperfusion 
(3 h ischemia; 2 h reperfusion) on day 21 post-inoculation. Mice were then sacrificed, and total foot tissue surrounding the inoculation site was excised and 
processed for real-time QPCR gene expression analysis for indicated genes. Results are presented as fold-change from inoculated sham-operated mice. *p < 0.05, 
**p < 0.01 between hAAT+/+ and WT groups. Unpaired two-tailed Student’s t-test was employed to assess differences between groups.
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transfection model, hAAT-expressing animals had significantly 
delayed growth rates of B16-F10 tumors even though circulat-
ing hAAT levels subsided ~14  days after tumor inoculation. 
C57BL/6-background hAAT+/+ mice (56) have been studied 
in multiple immunological models, including EAE, ulcerative 
colitis, transplantation, vaccination, and bacterial infections 
(1). Steady-state leukocyte compartments are at large similar to 
WT mice in general population size and activation profile (9); 
differences are primarily observed in modified outcomes of 
immunological activation.
In order to further establish the mechanism of action by 
which AAT inhibits tumor development in vivo, we examined the 
metastatic spread of B16-F10 cells. Using hAAT-treated animals, 
we found that hAAT treatment significantly reduced the number 
of metastatic nodules in the lungs. Interestingly, in hAAT-treated 
mice, leukocyte infiltration toward the area of metastatic foci was 
intact and displayed greater staining levels of CD45+ cells, com-
pared to vehicle-treated animals. Additionally, it was apparent 
that lymphocytic infiltration was submerged within the tumor 
mass, as opposed to the vehicle-treated group that displayed 
tumor masses forming discrete areas adjacent to non-invasive 
aggregates of mononuclear cells. hAAT thus appears to permit 
leukocyte extravasation given a strong enough inflammatory 
stimulus (e.g., establishment of metastatic cells).
Clearance of tumor cells may be executed by several immune 
cell types and in several discreet time spans. In hAAT-treated 
mice, survival rates of NK cell-sensitive RMA-S cells after i.v. 
inoculation were found to be comparable to those of NK cell-
insensitive RMA cells, suggesting that in vivo hAAT administra-
tion allows NK cell clearance of tumor cells, at least in this said 
time frame. Similar results were obtained when the survivability 
of i.v.-inoculated B16-F10 cells was compared to that of RMA 
cells.
B16-F10 cells may be lysed by sensitized CD8+ T cells as well 
as NK cells. In order to characterize the leukocyte compart-
ment primarily responsible for an increased antitumor immune 
response in hAAT-treated animals, we compared the progression 
of RMA (CD8+ T cell-sensitive, NK cell-insensitive) (70) and 
RMA-S (CD8+ T cell-insensitive, NK cell-sensitive) tumors (57) 
in direct inoculation experiments. While ablation of either NK 
cells or CD8+ T cells in B16-F10-inoculated animals is feasible, 
we employed the RMA/RMA-S inoculation model as these cells 
have been thoroughly studied in this context and reliably depict 
their distinct sensitivity to NK or CD8+ T cells. Here, while NK 
cell-sensitive tumors were unaffected by hAAT treatment, CD8+ 
T cell-sensitive tumors were significantly inhibited by hAAT 
treatment. These results suggest that, in contrast to observations 
collected from antigen-elicited immune settings, antitumor CD8+ 
T cell activity is in fact amplified by hAAT. Furthermore, CD8+ 
T cells proved to be indispensable for hAAT-induced inhibition 
of RMA tumors, based on a CD8+ T cell depletion experiment. 
Importantly, although NK cell activity did not appear to be 
elevated by hAAT treatment, it was not diminished either. These 
outcomes, as obtained by inoculation studies, suggest that NK 
cells or CD8+ T cell depletion studies should follow in order to 
fully elucidate the relevance of each cell subtype to the activity 
of AAT.
The characterization of tumor-infiltrating leukocytes yielded 
several interesting findings. For example, TAM expression 
of CD40 was significantly greater in hAAT-treated animals. 
Collectively, these observations correlate with the significantly 
elevated activation profile of tumor-infiltrating CD8+ T cells. 
Notably, such elevated CD8+ T cell activation was absent in the 
spleen of tumor-bearing animals, signifying the importance of 
local, rather than systemic, conditions exerted by hAAT treat-
ment in the whole animal.
Analysis of intra-tumor cytokine transcription levels suggests 
that AAT administration promotes a pro-cytotoxic inflammatory 
profile inside the tumor, including elevated transcription levels of 
IL-12p40, CD14, and IFNγ, and reduced transcription of IL-1Ra, 
VEGF, and α-SMA. This unique composition of expressed genes 
supports the presence of a profound distinction between tumor-
related activities of hAAT and benign conditions in its presence; 
islet grafts and endothelial cells were shown to express elevated 
levels of VEGF in the presence of hAAT (84), agreeing with the 
fact that the promoter for hAAT is hypoxia-responsive (85). 
Thus, the reduction in VEGF expression in the presence of hAAT 
suggests the presence of a distinguishing component that alters 
the transcriptome of hAAT-treated tumors and is independent 
of hypoxic conditions. Importantly, IFNγ transcription, but not 
IL-12p40 transcription, was affected by CD8+ T cell depletion; 
thus, hAAT appears to induce the upregulation of CD8+ T cell-
driving factors, such as IL-12p40, in a manner independent of the 
presence of CD8+ T cells. Earlier observations have determined 
that IL-2-dependent activities of CD8+ T cells are not directly 
affected by hAAT; we therefore suggest that hAAT-induced 
changes in the intra-tumor inflammatory gene profile are primar-
ily mediated by innate leukocytes, such as macrophages.
In order to further clarify the mechanism by which hAAT 
appears to induce greater antitumor activation of CD8+ T cells, 
future studies regarding hAAT may make use of tumor inocula-
tion models in conjunction with suppression of inflammation. 
Specifically, sorting out of intra-tumor macrophages, as well as 
antibody-mediated depletion of specific leukocyte compartments 
other than T cells could be used in order to clarify the interde-
pendency of hAAT-induced T cell activation and macrophages, 
as well as other innate immune populations.
Polarization of TAMs to a pro-inflammatory profile has been 
documented to facilitate antitumor responses (52, 86, 87). Our 
results suggest that under conditions of an evolving solid tumor, 
hAAT treatment induces elevated expression of CD40 by TAMs 
and thus the acquisition of pro-inflammatory properties. This 
favorable profile stands in contrast to the typical anti-inflamma-
tory and tissue-regenerative activities of hAAT, which include 
elevated IL-10 levels and further emphasizes the possibility that 
serum hAAT is distinct from tumor environment hAAT. Indeed, 
hAAT treatment seems to evoke diametrically opposed outcomes 
between tumor immunology and autoimmune responses. An 
attempted explanation for such differences in activity must take 
the vastly different immune-related environments that exist in 
tumors and in benign antigenic responses into account.
Nitric oxide holds a central and complex role in tumor 
development. Reports suggest that NO may reduce tumor cell 
proliferation and induce tumor cell apoptosis (88) but may also 
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FigUre s1 | haaT-treated animals retain similar short-term tumor cell 
clearance rates. (a,B) C57BL/6 mice (n = 5 per group) were pretreated with 
hAAT (2 mg per animal) 24 h prior to inoculation with differentially stained RMA 
(stained with DiO) and either (a) RMA-S or (B) B16-F10 (stained with DiD) cells 
(i.v. 1:1 ratio, 1 × 106 cells per animal). After 5 h, mice were sacrificed and cell 
ratios in the lungs were measured by flow cytometry. Mean ± SEM. Unpaired 
two-tailed Student’s t-test was employed to assess differences between groups.
FigUre s2 | haaT-treated mice display inhibited development of rMa, 
but not rMa-s tumors. C57BL/6 mice (n = 5 per group) were pretreated with 
hAAT (2 mg per animal) and after 24 h prior to inoculation with differentially 
stained RMA (stained with DiO) and B16-F10 (stained with DiD) cells (i.v. 1:1 
ratio, 1 × 106 cells per animal). After 5 h, mice were sacrificed and cell ratios in 
the lungs were measured by flow cytometry. Mean ± SEM. Unpaired two-tailed 
Student’s t-test was employed to assess differences between groups. C57BL/6 
mice (n = 6 per group) were pretreated with hAAT (2 mg per animal) 24 h prior to 
inoculation with RMA cells or RMA-S cells (1 × 105 cells per animal, s.c.); hAAT 
was administered every third day afterward and tumor sizes were determined 
routinely. Mean ± SEM, *p < 0.05. Unpaired two-tailed Student’s t-test was 
employed to assess differences between groups.
FigUre s3 | Pro-inflammatory profile of TaDcs in haaT-treated 
tumor-bearing mice. PBS- and hAAT-treated RMA tumor-bearing mice (n = 4 
per group) were sacrificed 13 days after RMA cell inoculation (1 × 105 cells per 
animal, s.c.). Tumors were dissociated, and cell populations were stained for 
indicated markers.
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